LXCHEM Q2 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹700 Cr
verified against source
Revenue YoY
-9%
reported change
EBITDA
₹37 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laxmi Organic reported a challenging Q2 FY26 with EBITDA declining 50% YoY to ₹37 crore, reflecting a 20% specialty revenue drop driven by agrochemical product phase-out (~10%), market price moderation (~7%), and deferred deliveries. EBITDA margin compressed 440bps to 5.3% as specialty margins hit 8.6%. The company maintains its ₹80 crore fluorination revenue target for FY26 (40-50% of peak), with the H facility phase 1 now operational under a multi-year customer supply agreement. Capex execution continues—₹800 crore expected capitalized by FY26 end, including world-scale ethyl acetate (Q4 FY26) and Hitachi SF6 replacement partnership (Q2 FY27). Essential volumes remain stable at 90-95% utilization. Key risks include prolonged feedstock price moderation, slower-than-expected fluorination ramp, and deferred order timing uncertainty impacting H2 recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Majority of ₹1,100 crore capex program to be capitalized by FY26 end, focused on H facility phase 2 completion and world-scale ethyl acetate commissioning.
- Company reaffirms 40-50% of peak revenue target for fluorination business in FY26, with steady ramp-up from current levels.
- 60 metric ton capacity for eco-efficient gas in high-voltage switchgear; ₹75 crore capex with ~1.2x asset turn expected; primarily serving export markets for Hitachi.
- Customer deliveries deferred from Q2 will materialize in Q3-Q4 FY26, providing revenue recovery in second half.
Risks flagged
- Management deflected questions on returning to 22-25% specialty EBITDA margins, citing only that H facility ramp and alternative agrochemical product mapping will help pivot in the right direction without committing to specific timelines.
- Analyst pressed on why fluorination revenue guidance of ~200 crore by FY27 remains minuscule relative to total revenues despite years of guidance; management acknowledged the fair question but provided limited expansion clarity beyond FY27.
- With 90-95% capacity utilization, analyst questioned why margins cannot improve; management clarified it's a function of spreads × volumes, not just volumes, and acknowledged spreads are at bottom of cycle.
- Analyst requested detailed breakdown of specialty revenue decline beyond the stated factors; management deferred to offline follow-up, indicating some granularity remains undisclosed.
Key quotes
- Bottom of the bottoms, somewhere in that range of $90 to $100 specifically for ETH.
- The majority of the capacity has been lined up contractually with that customer.
- We are at this point where you won't see double digit jumps but we will continue to sort of juice out our assets because we believe we are in a good cost position.
Research modules